Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Wang, Weiyuan ^a   Wen, Qiuyuan ^a   Xu, Lina ^a   Xie, Guiyuan ^a   Li, Jiao ^a   Luo, Jiadi ^a   Chu, Shuzhou ^a   Shi, Lei ^a   Huang, Donghai ^b   Li, Jinghe ^c   Fan, Songqing ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE B; S6 KINASE; EIF4EBP1 PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; PHOSPHOPROTEIN; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TARGET OF RAPAMYCIN KINASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DIFFERENTIATED NON KERATINIZING NASOPHARYNGEAL CARCINOMA; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; SURVIVAL RATE; TISSUE SECTION; UNDIFFERENTIATED NON KERATINIZING NASOPHARYNGEAL CARCINOMA; CHINA; METABOLISM; MIDDLE AGED; NASOPHARYNX TUMOR; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL; YOUNG ADULT;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; CHINA; FEMALE; HUMANS; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PHOSPHOPROTEINS; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84924123631     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106098     Document Type: Article

References (30)

1. Cho WC (2007)Nasopharyngeal carcinoma: molecular biomarker discovery and progress. Mol Cancer 6: 1.
2. Chou J, Lin YC, Kim J, You L, Xu Z, et al. (2008) Nasopharyngeal carcinoma-review of the molecular mechanisms of tumorigenesis. Head Neck 30: 946-963. (Pubitemid 352008957)
3. Suárez C1, Rodrigo JP, Rinaldo A, Langendijk JA, Shaha AR, et al. (2010) Current treatment options for recurrent nasopharyngeal cancer. Eur Arch Otorhinolaryngol 267: 18118-18124.
4. Restuccia DF, Hemmings BA (2010) From man to mouse and back again: advances in defining tumor AKTivities in vivo. Dis Model Mech 3: 705-720.
5. Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN (2006) AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 66: 5618-5623. (Pubitemid 43927113)
6. Goberdhan DI, Boyd CA (2009) mTOR: dissecting regulation and mechanism of action to understand human disease. Biochem Soc Trans 37: 213.
7. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev18: 1926-1945. (Pubitemid 39071573)
8. Pópulo H, Lopes JM, Soares P (2012) The mTOR signalling pathway in human cancer. Int J Mol Sci13: 1886-1918.
9. Holland EC, Sonenberg N, Pandolfi PP, Thomas G (2004) Signaling control of mRNA translation in cancer pathogenesis. Oncogene 23: 3138-3144. (Pubitemid 38638825)
10. Wiedmann MW, Caca K (2005) Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 5: 171-193. (Pubitemid 40694859)
11. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, et al. (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135. (Pubitemid 34155123)
12. Yoshizawa A, Fukuoka J, Shimizu S, Shilo K, Franks TJ, et al. (2010) Overexpression of phospho-eIF4E is associated with survival through AKT pathway in non-small cell lung cancer. Clin Cancer Res 16: 240-248.
13. Johnson SM, Gulhati P, Rampy BA, Han Y, Rychahou PG, et al. (2010) Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg 210: 767-776.
14. Woo HG, Park ES, Lee JS, Lee YH, Ishikawa T, et al. (2009) Identification of potential driver genes in human liver carcinoma by genomewide screening. Cancer Res 69: 4059-4066.
15. Xu ZZ, Xia ZG, Wang AH, Wang WF, Liu ZY, et al. (2013) Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab. Ann Hematol 92: 1351-1358.
16. She QB, Halilovic E, Ye Q, Zhen W, Shirasawa S, et al. (2010) 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors. Cancer Cell 18: 39-51.
17. Morgensztern D, McLeod HL (2005) PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16: 797-803. (Pubitemid 41215743)
18. Adamo B, Deal AM, Burrows E, Geradts J, Hamilton E, et al. (2011) Phosphatidylinositol 3-kinase pathway activation in breast cancer brain metastases. Breast Cancer Res 13: R125.
19. Morishita N, Tsukahara H, Chayama K, Ishida T, Washio K, et al. (2012) Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 59: 83-89.
20. Abedini MR, Muller EJ, Bergeron R, Gray DA, Tsang BK (2010) Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Oncogene 29: 11-25.
21. Li H, Kim J, Waldman T (2009) Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat Oncol 4: 1-10.
22. Bensouda Y, Kaikani W, Ahbeddou N, Rahhali R, Jabri M, et al. (2011)Treatment for metastatic nasopharyngeal carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis 128: 79-85.
23. Topisirovic I, Ruiz-Gutierrez M, Borden KL (2004) Phosphorylation of the eukaryotic translation initiation factor eIF4E contributes to its transformation and mRNA transport activities. Cancer Res J 64: 8639-8642. (Pubitemid 39552077)
24. Rojo F, Najera L, Lirola J, Jiménez J, Guzmán M, et al. (2007) 4E-binding protein 1, a cell signaling hallmark in breast cancer that correlates with pathologic grade and prognosis. Clin Cancer Res 13: 81-89. (Pubitemid 46121856)
25. Berven LA, Willard FS, Crouch MF (2004) Role of the p70S6K pathway in regulating the actin cytoskeleton and cell migration. Exp Cell Res 296: 183-195. (Pubitemid 38624640)
26. Xiao L, Wang YC, Li WS, Du Y (2009) The role of mTOR and phosphop70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res 28: 152.
27. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, et al. (2006) Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107: 1801-1811. (Pubitemid 44582949)
28. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, et al. (2006) Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 12: 3935-3941. (Pubitemid 44078078)
29. Chen J, Hu CF, Hou JH, Shao Q, Yan LX, et al. (2010) Research Epstein-Barr virus encoded latent membrane protein 1 regulates mTOR signaling pathway genes which predict poor prognosis of nasopharyngeal carcinoma. J Transl Med 8: 30.
30. Hu J, Wang N, Wang YJ (2013) XRCC3 and RAD51 Expression Are Associated with Clinical Factors in Breast Cancer. PLoS One. 8: e72104.